Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily AI-Based Treatment Adaptation under Weekly Offline MR Guidance in Chemoradiotherapy for Cervical Cancer 1: The AIM-C1 Trial.
Weykamp F, Meixner E, Arians N, Hoegen-Saßmannshausen P, Kim JY, Tawk B, Knoll M, Huber P, König L, Sander A, Mokry T, Meinzer C, Schlemmer HP, Jäkel O, Debus J, Hörner-Rieber J. Weykamp F, et al. Among authors: meixner e. J Clin Med. 2024 Feb 7;13(4):957. doi: 10.3390/jcm13040957. J Clin Med. 2024. PMID: 38398270 Free PMC article.
Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer-A Single-Center Experience and Review of the Literature.
Arians N, Oelmann-Avendano JT, Schmitt D, Meixner E, Wark A, Hoerner-Rieber J, El Shafie RA, Lang K, Wallwiener M, Debus J. Arians N, et al. Among authors: meixner e. Cancers (Basel). 2020 Aug 15;12(8):2301. doi: 10.3390/cancers12082301. Cancers (Basel). 2020. PMID: 32824243 Free PMC article.
Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial.
Forster T, Hommertgen A, Häfner MF, Arians N, König L, Harrabi SB, Schlampp I, Köhler C, Meixner E, Heinrich V, Weidner N, Hüsing J, Sohn C, Heil J, Golatta M, Hof H, Krug D, Debus J, Hörner-Rieber J. Forster T, et al. Among authors: meixner e. Radiother Oncol. 2021 Oct;163:165-176. doi: 10.1016/j.radonc.2021.08.019. Epub 2021 Sep 1. Radiother Oncol. 2021. PMID: 34480960 Clinical Trial.
Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults.
Eichkorn T, Bauer J, Bahn E, Lischalk JW, Meixner E, Sandrini E, Regnery S, Held T, Hörner-Rieber J, Alber M, Herfarth K, Debus J, König L, Harrabi S. Eichkorn T, et al. Among authors: meixner e. Radiother Oncol. 2022 Jul;172:54-64. doi: 10.1016/j.radonc.2022.05.005. Epub 2022 May 11. Radiother Oncol. 2022. PMID: 35568281
Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.
König L, Hörner-Rieber J, Forsthoefel M, Haering P, Meixner E, Eichkorn T, Krämer A, Mielke T, Tonndorf-Martini E, Haefner MF, Debus J, Lischalk JW. König L, et al. Among authors: meixner e. Cancers (Basel). 2022 May 13;14(10):2409. doi: 10.3390/cancers14102409. Cancers (Basel). 2022. PMID: 35626013 Free PMC article.
38 results